News and Announcements
AI-Driven Venture Capital Investing: Insights from John Sharp, Partner at Hatcher+
- Published March 28, 2023 5:25AM UTC
- Publisher Jade Miguel
- Categories Capital Insights
As the venture capital industry evolves, it’s crucial to stay on top of emerging strategies and technologies.
Join John Sharp, Partner at Hatcher +, as he shares his expertise on how venture capital has developed over time and what the future holds.
Learn about the impact of AI-driven investing strategies, historical data, and proven methodologies.
#VentureCapital #Investing #Strategy #WholesaleInvestor
Capital Insights
Jamie Dimon: Navigating a World of Uncertainty – From Recession Risks to Geopolitical Tensions
In a candid interview with Bloomberg, JPMorgan Chase CEO Jamie Dimon offered a nuanced perspective on the current global economic landscape, a panorama he describes as rife with “a lot of uncertainty.” From lingering recession fears in the US to the complex interplay of trade wars and geopolitical tensions, Dimon, ever the realist, painted a […]
Wholesale Investor and CapitalHQ Sign Exclusive Master Licence with inQ Innovation Global to Provide Access to India’s High-Growth Startup Market
Wholesale Investor and inQ Innovation have forged a strategic partnership, granting global investors direct access to India’s rapidly expanding innovation ecosystem. This exclusive three-year agreement leverages CapitalHQ’s technology to streamline fundraising for Indian startups and expand deal flow for WI’s 45,000-strong investor network, aligning with India’s 2030 Vision for economic growth and innovation.
EBR Systems: Aussie Medtech Ready to Disrupt $3.6B Heart Failure Market with Leadless Pacemaker
Andrew Shute, Senior Vice President of Business Development at EBR Systems, is confident that his Australian medical device company is poised to make a significant impact on the global cardiac rhythm management market. The focus? A novel leadless pacemaker designed to revolutionise treatment for heart failure patients. After years of development and rigorous clinical trials, […]
Backed By Leading Investment Groups and Family Offices
